A Clinical Trial to Investigate Biomarker Effects of Pre-Surgical Treatment With DDR Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) Who Are Planned to Undergo Surgery That is Likely to be Followed by Radiotherapy and/or Chemotherapy.
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Oct 2017
At a glance
- Drugs AZD 6738 (Primary) ; Olaparib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 05 Oct 2017 Planned End Date changed from 1 Jan 2019 to 28 Aug 2019.
- 05 Oct 2017 Planned primary completion date changed from 1 Jan 2019 to 28 Aug 2019.
- 05 Oct 2017 Planned initiation date changed from 1 Mar 2017 to 11 Oct 2017.